规格 | 价格 | 库存 | 数量 |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
体外研究 (In Vitro) |
Fatostatin Hydrobromide (0.1-1 μM;3 d) 抑制雄激素非关键悬浮幅度 (IC50=0.1 μM),与已知的 IGF1 信号反馈无关。 Fatostatin Hydrobromide 抑制 3T3-L1 细胞中的激素脂肪生成[1]
|
---|---|
体内研究 (In Vivo) |
通过降低甘油三酯 (TG) 储存,氢溴酸 Fatostatin(30 mg/kg;150 mL;腹膜内注射;每日一次,持续 28 天)可降低肥胖个体的体重、改善脂肪肝疾病并降低高血压[2]。
|
细胞实验 |
细胞增殖测定[1]
细胞类型: DU-145 细胞 测试浓度: 0.1, 1 μM 孵育时间: 3 天 实验结果: 损害 IGF1 诱导的生长,IC50 为 0.1 μM。 |
动物实验 |
Animal/Disease Models: Homozygous male obese (ob/ob) mice (C57BL/6J), 4 to 5 weeks old [2]
Doses: 30 mg/kg; 150 mL Route of Administration: intraperitoneal (ip) injection; one time/day for 28 days Experimental Results: Body weight, blood glucose, and hepatic fat accumulation are prevented in obese ob/ob mice even without controlling food intake. |
参考文献 |
[1]. Choi Y, et al. Identification of bioactive molecules by adipogenesis profiling of organic compounds. J Biol Chem. 2003 Feb 28;278(9):7320-4.
[2]. Kamisuki S, et al. A small molecule that blocks fat synthesis by inhibiting the activation of SREBP. Chem Biol. 2009 Aug 28;16(8):882-92. |
分子式 |
C18H19BRN2S
|
---|---|
分子量 |
375.3259
|
CAS号 |
298197-04-3
|
相关CAS号 |
Fatostatin;125256-00-0
|
SMILES |
Br[H].S1C([H])=C(C2C([H])=C([H])C(C([H])([H])[H])=C([H])C=2[H])N=C1C1C([H])=C([H])N=C(C=1[H])C([H])([H])C([H])([H])C([H])([H])[H]
|
存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
溶解度 (体外) |
DMSO : ~25 mg/mL (~66.61 mM)
|
---|---|
溶解度 (体内) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.54 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 1 mg/mL (2.66 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. 请根据您的实验动物和给药方式选择适当的溶解配方/方案: 1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL; 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果,工作液请现配现用! 6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
制备储备液 | 1 mg | 5 mg | 10 mg | |
1 mM | 2.6643 mL | 13.3216 mL | 26.6432 mL | |
5 mM | 0.5329 mL | 2.6643 mL | 5.3286 mL | |
10 mM | 0.2664 mL | 1.3322 mL | 2.6643 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。
Fatostatin inhibits SREBP activation.J Lipid Res. 2016 Aug;57(8):1564-73. Lipid does not rescue fatostatin inhibition of cell growth.J Lipid Res. 2016 Aug;57(8):1564-73. td> |
Fatostatin blocks ER-to-Golgi transport of SCAP.J Lipid Res. 2016 Aug;57(8):1564-73. Fatostatin inhibits growth inSCAPknockout cells.J Lipid Res. 2016 Aug;57(8):1564-73. td> |
Fatostatin inhibition of SREBP does not require INSIG. |